At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Germany based CFO’ operating in the Medical space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Michael Brosnan
Chief Financial Officer of Fresenius Medical Care
Michael Brosnan was appointed chief financial officer on January 1, 2010. Previously, he served as chief financial officer of Fresenius Medical Care North America for seven years. He joined the company in 1998 as vice president of Finance and Administration for Spectra Renal Management, the company’s laboratory services organization. Subsequently, he assumed several executive functions at Fresenius Medical Care North America.Prior to joining the company, he held senior financial positions at Polaroid Corporation and was an audit partner at
Follow Michael Brosnan:
About Fresenius Medical Care: Fresenius Medical Care is a healthcare company that provides dialysis treatment for those with chronic kidney diseases.
Philip Magoulas
CFO & Co-Founder of Bestsmile
Co-founder and managing director Alexander Henn is mainly responsible for markets, marketing and business development. He first accessed the digital world during the stock market boom in 1999 with the Boersen-Investor.de exchange platform and founded the first German shop for vitamin products at the age of 15. He later founded other companies such as the online shop Libute.de and Xantera AG. This young entrepreneur graduated from high school by taking evening classes in Munich and then, in addition to his professional activity, studied law at Ludwig-Maximilians-Universität in Munich. During his free time, Alexander Henn devotes himself to politics and history and relaxes listening to classical or electronic music.
Follow Philip Magoulas:
About Bestsmile: Bestsmile is an orthodontics company that specializes in clear aligner and veneer treatments for your teeth.
Thomas Dürre
Chief Financial Officer of Isotopen Technologien München
Thomas accepted the position as Chief Financial Officer at ITM Isotopen Technologien München AG in April 2016. Before that he worked for 3 years as Senior Vice President at Software AG and was responsible for all aspects of Global Integration Management. Prior to this he was CFO at alfabet AG for 15 years and headed the successful sale and merger of alfabet AG to Software AG. Thomas started his career in 1991 at Ernst & Young and worked from 1996 until 1998 as Controller Germany for the US based international waste management company BFI. Thomas has 25 years of work experience in finance, especially in the international expansion and growth of start-ups and preparation as well as execution of exit strategies in private equity companies. He holds a Masters Degree in Business Administration (Dipl.-Kfm.) from the University of Cologne (Germany).
Follow Thomas Dürre:
About Isotopen Technologien München: Isotopen Technologien München is a privately held biotechnology and radiopharmaceutical group of companies.
Federico Bursgens
Managing Director and CFO of GNA Biosolutions
Federico holds the post of Managing Director and CFO of GNA Biosolutions. His primary responsibilities are GNA’s finances as well technology-wise for the optoelectronic and software development. Federico has started his entrepreneurial career in high school and thus gained many years of business planning experience. Federico began his undergraduate studies of physics at the University of Munster/Germany and then enrolled at the Universities of Wurzburg/Germany and the University of Texas at Austin, where he earned his Master’s degree in physics in 2003. During his entire studies Federico was a fellow of the German National Academic Foundation (Studienstiftung). Afterwards, Federico moved to Munich/Germany where he worked in the Center for nanoscience and obtained his PhD in physics from Ludwig-Maximilians-Universität in 2008. He is author and co-author of 16 peer-reviewed scientific papers on detection technology.
Follow Federico Bursgens:
About GNA Biosolutions: GNA Biosolutions is a private molecular diagnostics company.
Anne Burger
CFO & Co-Founder of Breath Therapeutics
Anne Burger has over 15 years expertise in senior finance functions for biotech and Medtech companies throughout Europe and has served as lead advisor in numerous transactions, financings and structuring projects. Recently, Burger was CFO for Rigontec GmbH, an immune-oncology biotechnology company. She supported Rigontec’s fundraising activities and had an active role in the execution of the Trade sale to MSD (deal volume up to 464 M€). Throughout her career, Burger held several CFO and advisor positions in the life sciences and healthcare sector and was responsible for fundraising, executing trade sales and licensing agreements, and preparing for IPOs. Burger earned a graduate degree in Business Administration (Ludwig-Maximilian-Universität Munich, Honors) and successfully passed graduate studies in public health (Ludwig-Maximilian-Universität Munich).
Follow Anne Burger:
About Breath Therapeutics, Catalym: Breath Therapeutics is a private clinical-stage biopharmaceutical company.
Martin Reichhuber
Chief Financial Officer of 4TEEN4 Pharmaceuticals
Follow Martin Reichhuber:
About 4TEEN4 Pharmaceuticals: 4TEEN4 Pharmaceuticals develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions.
Friedrich Jacobi
CFO & Managing Director of Fiagon
Dr. Jacobi serves Fiagon as the Chief Financial Officer and as a member of the Board of Directors. Friedrich spearheads Fiagon’s financial operations, overseeing Investor Relations, Financial Corporate Strategy, and Treasury. In addition, he serves as the global head of Human Resources, Legal, and Compliance. Friedrich joined Fiagon in the first quarter of 2017, bringing more than 16 years of experience in medical and life science industries. He further adds over 20 years of business administration and management experience to the executive team. Pulling from his extensive background with both startup and large companies, Friedrich offers considerable experience transitioning a company from the startup phase, into high growth, mid-capitalization, and acquisition. Most recently, Friedrich served as CFO and Business Manager for Allergopharma, the global allergy subsidiary of Merck KGaA, playing a vital role in the high growth and performance of the company during his nine-year tenure. Friedrich is a proponent of the agile business model implemented in Fiagon. He advocates a proactive management style that allows for maximizing efficient use of company resources. In line with Fiagon’s core values, Friedrich ascribes to employee empowerment methodology, seeking to support and promote employee growth. Friedrich earned his Ph.D. in Business Administration from the University of St. Gallen in St. Gallen, Switzerland. Prior to his doctoral program, he received his Master’s Degree in Business Administration from James Madison University in Virginia, USA.
Follow Friedrich Jacobi:
About Fiagon: Fiagon develops clinical navigation systems that reimagine image guidance by improving the function of electromagnetic navigation.
Jens Holstein
Chief Financial Officer of MorphoSys
Jens Holstein joined MorphoSys from Fresenius Kabi AG, where he most recently served as Regional CFO for the region EME (Europe/Middle East) and as Managing Director of Fresenius Kabi Deutschland GmbH. Over the last almost 16 years at Fresenius he had held a variety of financial and general management positions. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of Fresenius ProServe GmbH and Finance Director and Labor Director of the company’s subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects & Service business unit of Fresenius AG and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry, with positions in Frankfurt and London. Mr. Holstein holds a Diploma in Business Administration from University of Münster. He currently does not hold any other board memberships.
Follow Jens Holstein:
About MorphoSys: MorphoSys is a biotechnology company focused on the research and development of fully human antibodies.
Wolf-Peter Werner
Co-Founder and CFO of Mecuris
Follow Wolf-Peter Werner:
About Mecuris: Mecuris develops tailor-made prostheses and orthoses from the 3D printer.
Christian Nafe
Managing Director and Chief Financial Officer of leon nanodrugs
Christian Nafe is the Managing Director & Chief Financial Officer of leon-nanodrugs.He brings in more than 25 years of successfully working in corporate finance, controlling and finance. Christian held leading management positions in different roles in worldwide operating companies, since 2000 with a focus on life sciences. During this time, he successfully managed numerous license contracts, asset and share deals as well as supply agreements. He recently served as CEO/CFO at BioNet Holding GmbH, BioNet Ventures GmbH and BioNet Pharma GmbH (former Scil Technology GmbH). Christian graduated with honors as Dipl. Kaufmann in Business Administration from University Regensburg.
Follow Christian Nafe:
About leon nanodrugs: leon-nanodrugs is a nanotechnology-based drug development company.
Melanie Hammerschmidt-Broman
Chief Financial Officer of Leica Microsystems
Follow Melanie Hammerschmidt-Broman:
About Leica Microsystems: Leica Microsystems designs and produces precision optics systems for the analysis of microstructures.
Florian Fischer
CFO of Activaero
Dr. Fischer joined Affimed in 2005 as CFO on a part-time basis, transitioning into the full time CFO position at the Company’s IPO in 2014. Florian has a strong track record in various Biotech/MedTech executive positions, as lead advisor in a variety of transactions and financings in the life sciences and healthcare sector. Dr. Fischer is founder of MedVenture Partners – a corporate finance and strategy advisory company focusing on the life sciences and healthcare industry. Dr. Fischer was Chief Financial Officer of Activaero GmbH from 2002 until 2011 and responsible for corporate development until Activaero’s acquisition by Vectura in 2014. He also served as Chief Financial Officer of Vivendy Ltd. from 2008 until 2013 and as Managing Director of AbCheck in 2009. Prior to founding MedVenture Partners, Dr. Fischer worked with KPMG for more than six years until 2002, where he was responsible for biotech and healthcare assignments. Before joining KPMG, he worked for Deutsche Bank AG. Dr. Fischer is also a Director of Amphivena. He holds a graduate degree in business administration from Humboldt University, Berlin and a Ph.D. in public health from the University of Bielefeld.
Follow Florian Fischer:
About Activaero, Affimed: Activaero develops breathing technologies for patients suffering from severe respiratory diseases.
Georg Kox
Managing Director & CFO of Sividon Diagnostics
1999: project manager for the Bio-Gen-Tec-NRW state initiative; financing of promising biotech start-ups 2001: business development and license management for a medium-sized pharmaceutical company 2002: International Marketing and Sales at DASGIP AG. 2005: Investment Manager at Intelligent Venture Capital GmbH; focus on life science and technology-based start-ups. 2008: CEO of Intelligent Venture Consulting AG. Active support for entrepreneurs on strategic issues in marketing, sales and finance Since 11/2010: Managing Partner of Sividon Diagnostics GmbH
Follow Georg Kox:
About Sividon Diagnostics: Sividon Diagnostics develops advanced diagnostics that facilitate therapeutic discovery.
Thomas Taapken
CFO of InflaRx
Follow Thomas Taapken:
About InflaRx: InflaRx develops new therapeutics in the field of acute and chronic inflammation.
Anne Burger
CFO of Rigontec
Follow Anne Burger:
About Rigontec: Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.
Reinhard Rubow
Chief Financial Officer of Retina Implant
Reinhard Rubow worked in various leading financial functions at several well-known companies before becoming commercial director of the Institute of Natural Sciences and Medicine (NMI) at the University of Tübingen in Reutlingen. From there, he ventured into the start-up company Retina Implant AG.
Follow Reinhard Rubow:
About Retina Implant: Retina Implant is a biotech company which develops subretinal implants for partially sighted and blind patients.
Benjamin Steimle
CFO & Co-Founder of Cytena
Follow Benjamin Steimle:
About Cytena: Cytena develops single-cell printing technology for cell research and professional diagnostics.
Philipp Naegelein
Co-Founder and CFO of MEDIKURA
Follow Philipp Naegelein:
About MEDIKURA: MEDIKURA develops digital infrastructure for drug safety. The goal is to make the drug safety as safe as possible.
Rudolf Schulze Vohren
Chief Financial Officer of Nano4Imaging
Entrepreneur and Consultant highly experienced in business development. In 2011 he co-founded Nano4Imaging GmbH and, in 2007 IN LIFE Management AG. Rudolf serves IN LIFE Management AG as Chairman of the Supervisory Board. IN LIFE specializes in solving risk- and time-critical management problems in life sciences and health care through interim executives. Rudolf is Managing Director of BBM VOHREN GmbH, which he founded in 2004. BBM VOHREN is active in the area of international business development and building new ventures. During previous 18 years Rudolf worked for BAYER AG on international assignments in Asia, Africa/Middle East, Europe and Latin America. Industries served include Non-Profit-Organisations, Pharma/OTC, Biotechnology, Nanotechnology, in-vitro Diagnostics/IVD, Life Science Research, Medical Devices/MedTech, Fine Chemicals, Agrochemicals and Veterinay. Specialties: High premium on: – Acquisition of high value projects and customers – Structuring and executing (interim) management projects – Growth strategies and international market entry
Follow Rudolf Schulze Vohren:
About Nano4Imaging: Nano4Imaging produces and uses medical devices and implants visible for medical interventions to monitor their function (e.g under MRI).
Felix Dietrich
Co-Founder & CFO of Amparo
Follow Felix Dietrich:
About Amparo: Disrupting prosthetic care technology with human-centered design.
Albert Christian Schauer
Chief Financial Officer of Avra Medical Robotics
Albert Christian Schauer, BRA, CPA, CTA has been Chief Financial Officer of AVRA Surgical Robotics Inc. and serves as its Principal Accounting Officer. Albert Schauer has been President and Chief Executive Officer of PharmOptima LLC, a pre-clinical contract research company based in Portage, Michigan. He served as the Chief Executive Officer of Eimo Technologies, Inc. and also served as its Chief Financial Officer. Following almost 10 years with Ernst & Young(formerly Ernst & Ernst ) in Kalamazoo and Cleveland, he joined Clausing Corporation in 1974 as Chief Financial Officer, and served that Company for 25 years in various senior management positions, the last 15 years as Chairman and Chief Executive Officer. For the prior 15 years, he was employed by Clausing Industrial Inc., a subsidiary of The 600 Group PLC, headquartered in the United Kingdom.
Follow Albert Christian Schauer:
About Avra Medical Robotics: AVRA was organized by a senior leadership team with broad and deep experience in medical research, innovation